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Background: Guidelines from the Japanese Circulation Society recommend prophylaxis with anticoagulation plus
intermittent pneumatic compression or graduated compression stockings (GCS) among patients at the highest risk
for developing venous thromboembolism (VTE). However, the benefits of concomitant GCS use for patients
undergoing total knee arthroplasty (TKA) and receiving anticoagulation remain unknown. In this study, the efficacy of
GCS plus anticoagulation compared with anticoagulation alone was evaluated among patients undergoing TKA.
Methods: This study is a post hoc analysis of a previously reported phase 3 trial involving patients undergoing TKA. In
the primary study, which permitted the use of GCS for mechanical prophylaxis, patients were randomized to receive
edoxaban 30 mg once daily or enoxaparin 20 mg twice daily for 11 to 14 days following TKA. The primary endpoint
was the incidence of VTE, a composite of symptomatic deep vein thrombosis (DVT), symptomatic pulmonary
embolism (PE), and asymptomatic DVT. Treatment comparisons were performed using the chi-square test, and
the 95 % confidence intervals were calculated.
Results: Among patients receiving edoxaban, the incidence of VTE was 3.8 and 5.8 % for patients with and
without GCS, respectively. For patients receiving enoxaparin, VTE incidence was 8.4 and 20.8 % among those
with and without GCS, respectively. Overall, VTE incidence was 6.0 and 13.0 % for anticoagulated patients with and
without GCS mechanical prophylaxis, respectively. No deaths or symptomatic PE were reported during this study.
Conclusions: Although the incidence of VTE was >2-fold lower among patients receiving anticoagulation plus GCS
compared with those receiving anticoagulation alone, statistical significance was not achieved. Further studies are
required to confirm the findings of this preliminary analysis.
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Table 1 Use of mechanical prophylaxis (efficacy analysis set)





N = 73GCS IPC
o x 129 136 39
o o 238 274 15
x o 123 92 10
x x 104 1 9
GCS graduated compression stockings, HFS P3 hip fracture surgery phase 3
study, IPC intermittent pneumatic compression, THA P3 total hip arthroplasty
phase 3 study, TKA P3 total knee arthroplasty phase 3 study
o = patients receiving indicated treatment; x = patients without the
indicated treatment
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Major lower limb orthopedic surgery—such as total knee
arthroplasty (TKA), total hip arthroplasty (THA), and
hip fracture surgery (HFS)—is a significant risk factor
for postoperative venous thromboembolism (VTE),
encompassing deep vein thrombosis (DVT) and pul-
monary embolism (PE) [1, 2]. For patients undergoing
lower limb orthopedic surgery, several pharmacological
and mechanical therapies are available for the prevention
of VTE, including graduated compression stockings
(GCS), which are a convenient and inexpensive mechan-
ical prophylaxis measure [1]. Although the exact mech-
anism of action of GCS remains unclear, they are
believed to reduce the total cross-sectional area of the
leg veins, thereby increasing venous blood flow velocity
and preventing venous stasis in the lower limbs [3].
Guidelines from the Japanese Circulation Society rec-
ommend the use of GCS for prophylaxis among patients
at an intermediate risk for VTE [1]. Anticoagulation or
intermittent pneumatic compression (IPC) is recom-
mended for patients at a high risk for VTE, such as
those undergoing major orthopedic surgery, while antic-
oagulation plus IPC or GCS is recommended for pa-
tients at the highest risk for VTE [1]. However, the
efficacy of the combined treatment of anticoagulation
with GCS relative to anticoagulation alone for VTE pre-
vention among patients undergoing major lower limb
orthopedic surgery has not been evaluated. In this study,
an exploratory analysis was performed to evaluate the ef-
ficacy of GCS combined with enoxaparin or edoxaban, a
direct, oral, factor Xa inhibitor, using data from a phase
3 clinical study that assessed the efficacy and safety of
edoxaban (vs enoxaparin) for the prevention of postop-
erative VTE in patients undergoing TKA.
Methods
Study selection
Three phase 3 studies involving patients undergoing
TKA (TKA P3; STARS E-3 trial) [4], THA (THA P3;
STARS J-5 trial) [5], or HFS (HFS P3; STARS J-4 trial)
[6] were considered for inclusion in this analysis. A total
of 716, 610, and 92 patients were enrolled in the TKA
P3 [4], THA P3 [5], and HFS P3 [6] studies, respectively,
of whom 594, 503, and 73, respectively, were evaluable
for efficacy. These 3 studies were conducted between
October 2008 and January 2010. In all 3 studies, the
concomitant use of any method of mechanical prophy-
laxis, including GCS and IPC, was permitted. Table 1
summarizes the number of patients available for efficacy
analysis stratified by the method of mechanical prophy-
laxis. Since there were few patients without mechanical
prophylaxis in the THA P3 (1 patient) and HFS P3 (9
patients) studies, these 2 studies were excluded from the
present analysis. In TKA P3, 129 patients received GCSalone as mechanical prophylaxis and 104 patients had
no mechanical prophylaxis. Data from the TKA P3 study
were included in the present analysis.Study design and site selection
TKA P3 was a randomized, double-blind, parallel-group
study performed by the double-dummy method (Fig. 1)
[4]. Edoxaban (30 mg) was administered orally once a
day, while enoxaparin (20 mg) was injected subcutane-
ously twice a day for 11 to 14 days in accordance with
standard practice. Edoxaban was administered 6 to 24 h
after surgery, whereas enoxaparin treatment commenced
24 to 36 h following surgery. Venography was performed
within 24 h after the last dose, and occurrence of VTE
was determined by an independent Clinical Event Com-
mittee that was blinded to the treatment of the patients.
The primary efficacy endpoint was the percentage of pa-
tients who developed asymptomatic DVT, symptomatic
DVT, or symptomatic PE (the incidence of VTE).
In TKA P3, 716 patients were enrolled at 71 sites. To
exclude possible bias due to selection of GCS depending
on the severity of illness or the VTE risk of each patient,
18 sites where GCS had been used for selected patients
were excluded from the present analysis. Thus, the
remaining 422 patients from 53 sites were considered
for inclusion in the present analysis. To avoid the influ-
ence of other mechanical methods (eg, IPC), patients
who had also used IPC were excluded as well. Thus, the
present analysis compared 101 patients who had used
GCS alone as mechanical prophylaxis (53 from the
edoxaban group and 48 from the enoxaparin group) with
100 patients without any mechanical prophylaxis (52
from the edoxaban group and 48 from the enoxaparin
group), so a total of 201 patients were included in this
assessment of the efficacy of GCS.Statistical analysis
The incidence of VTE was summarized using descriptive
statistics. Treatment comparisons were made using the
χ2 test and the 95 % confidence interval was calculated.
Fig. 1 Study design (phase 3 total knee arthroplasty study) [4]. aTreatment with oral edoxaban commenced 6–24 h postoperatively. bTreatment
with subcutaneous enoxaparin commenced 24–36 h postoperatively. cFollow-up occurred 25–35 days after the last administered dose
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The demographics and baseline characteristics of pa-
tients included in this subanalysis are presented in
Table 2. The mean age, body weight, and creatinine
clearance were not different among patients regardless
of anticoagulant and/or mechanical prophylaxis use.Table 2 Demographic and baseline characteristics summary










Duration of surgery, (h:min)
Mean ± SD
Tourniquet use during surgery, n (%)




Duration from the end of surgery to the start of anticoagulation, (h:min)
Mean ± SD
Duration from surgery to ambulation (days)
Mean ± SD
Duration of treatment (days)
Mean ± SD
Duration of GCS use (days)
Mean ± SD
CLcr creatinine clearance, GCS graduated compression stockings, SD standard deviatTourniquet use was lower, whereas the use of epidural
and lumbar anesthesia was higher among patients re-
ceiving GCS relative to those without any mechanical
prophylaxis. This difference was due to facility-specific
practices; facilities employing GCS for prophylaxis had
lower rates of tourniquet or general anesthesia use.No mechanical prophylaxis GCS alone
N = 100 N = 101
Edoxaban Enoxaparin Edoxaban Enoxaparin
N = 52 N = 48 N = 53 N = 48
11 (21.2) 9 (18.8) 8 (15.1) 9 (18.8)
41 (78.8) 39 (81.3) 45 (84.9) 39 (81.3)
70.9 ± 7.9 71.7 ± 7.8 73.5 ± 6.1 73.2 ± 7.0
63.2 ± 10.2 64.3 ± 11.9 56.8 ± 10.2 60.3 ± 10.1
78.3 ± 24.6 76.2 ± 26.5 71.1 ± 20.1 74.9 ± 20.0
2:03 ± 0:44 1:59 ± 0:35 1:42 ± 0:26 1:45 ± 0:24
50 (96.2) 46 (95.8) 42 (79.2) 38 (79.2)
43 (82.7) 35 (72.9) 24 (45.3) 20 (41.7)
8 (15.4) 7 (14.6) 17 (32.1) 14 (29.2)
24 (46.2) 24 (50.0) 38 (71.7) 34 (70.8)
20:31 ± 2:39 30:41 ± 3:26 19:43 ± 2:59 27:08 ± 2:30
2.2 ± 0.7 2.4 ± 0.8 3.6 ± 1.4 3.8 ± 2.1
12.1 ± 1.6 11.6 ± 2.6 12.4 ± 1.6 12.4 ± 1.7
- - 9.5 ± 2.7 9.6 ± 2.7
ion
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and enoxaparin groups, respectively. The mean (stand-
ard deviation) time interval between surgery and the
start of postoperative anticoagulant therapy was 20 h
and 7 min (2 h and 50 min) for the edoxaban group and
28 h and 54 min (3 h and 29 min) for the enoxaparin
group. Enoxaparin was administered between 24 to 36 h
after surgery, in accordance with enoxaparin prescribing
practices [7], accounting for this difference in initiation
of anticoagulation following surgery.
In the edoxaban group, the incidence of VTE was 3.8 %
(2/53) and 5.8 % (3/52) for patients with and without GCS
mechanical prophylaxis, respectively (p = 0.6312; Table 3).
In the enoxaparin group, the incidence of VTE was 8.4 %
(4/48) for patients using GCS alone as mechanical
prophylaxis, and 20.8 % (10/48) for patients without
mechanical prophylaxis (p = 0.0827). Combining the 2
groups, the incidence of VTE was 6.0 % (6/101) and
13.0 % (13/100) for patients with and without GCS mech-
anical prophylaxis. There were no deaths in this study. Of
the 201 patients included in this analysis, no instances of
symptomatic or asymptomatic PE and no instances of
symptomatic DVT were observed; all patients had asymp-
tomatic DVT.
Discussion
Anticoagulants prevent VTE by suppressing hypercoagu-
lability [8], while GCS prevent VTE by increasing the
venous blood flow velocity and impeding venous stasis
in the legs [3]. Thus, 2 independent elements of Virch-
ow’s thrombogenic triad (“hypercoagulability” and “ven-
ous stasis”) [8] are targeted when prophylaxis with
anticoagulant therapy and GCS is combined. This is
thought to be the mechanism by which combined ther-
apy achieves a greater reduction in the incidence of VTE
after major lower limb orthopedic surgery. Few studies
have examined the efficacy of combined anticoagulant
and GCS therapy relative to anticoagulation alone for
VTE prevention among patients undergoing major
orthopedic surgery [9]. A study involving patients under-
going THA in the UK revealed that the incidence of
DVT or PE was not significantly different betweenTable 3 Incidence of VTEa in patients using GCS for prophylaxis
No mechanical prophylaxis
Mechanical prophylaxis with GCS alone
Chi-square test
Difference between with and without GCS treatment groups
95 % CI of the difference shown by the score test
CI confidence interval, GCS graduated compression stockings, VTE venous thromboe
aAll instances of VTE were asymptomatic DVT; no instances of symptomatic or asympatients receiving enoxaparin plus GCS compared to
those receiving enoxaparin alone [10]. However, this
study was limited by its small sample size, with 32
patients randomized to each treatment group [10].
Among Swedish patients undergoing THA, combined
treatment with dextran (infused at anesthesia and for
2 days following surgery) and GCS was more effective
for postoperative DVT prevention than treatment
with dextran alone [11].
Although Japanese guidelines recommend the use of
GCS with anticoagulation for prophylaxis among pa-
tients at the highest risk for VTE [1], the efficacy of this
combined treatment relative to anticoagulation alone for
Japanese patients undergoing major orthopedic surgery
has previously not been reported. The findings from the
present study suggest that concomitant treatment with
anticoagulation and GCS resulted in a >2-fold reduction
in VTE incidence relative to anticoagulation alone
among Japanese patients undergoing TKA, although this
difference was not statistically significant. Addition of
GCS therapy led to a numerically greater reduction in
VTE incidence primarily among patients receiving enox-
aparin, while this reduction was less pronounced among
those receiving edoxaban. This difference may have
arisen partly because edoxaban was started earlier in the
postoperative period; as a result, there was a smaller
margin for further reduction of VTE occurrence with
the addition of GCS among patients treated with edoxa-
ban. Given the limited number of patients in this ana-
lysis (n = 201), and the delay in the initiation of
anticoagulation with enoxaparin relative to edoxaban,
these exploratory results need to be confirmed in larger,
prospective, randomized trials.
Conclusion
To evaluate the efficacy of GCS for prevention of VTE,
an exploratory analysis was performed by using data
from a phase 3 clinical study of postoperative prophy-
laxis with edoxaban vs enoxaparin in patients undergo-
ing TKA. The results of the analysis suggested that the
occurrence of VTE was numerically lower among pa-
tients receiving anticoagulant plus GCS therapy relativeEdoxaban Enoxaparin Total
N = 105 N = 96 N = 201
5.8 % (3/52) 20.8 % (10/48) 13.0 % (13/100)
3.8 % (2/53) 8.4 % (4/48) 6.0 % (6/101)
p = 0.6312 p = 0.0827 p = 0.0872
–2.0 –12.5 –7.1
−12.2, 7.8 −26.8, 1.9 −15.7, 1.2
mbolism
ptomatic PE or symptomatic DVT were observed
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ference was not statistically significant. Further studies are
required to confirm the findings of this preliminary ana-
lysis. Additionally, due to the limitations of this analysis,
further studies need to be performed to evaluate the rela-
tive prophylactic efficacy of combined anticoagulant and
GCS therapy compared with anticoagulation alone.
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